{
    "clinical_study": {
        "@rank": "137706", 
        "arm_group": [
            {
                "arm_group_label": "AEZS-108", 
                "arm_group_type": "Experimental", 
                "description": "AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a therapeutic exploratory Phase 2 study evaluating  AEZS-108  compared to standard\n      single agent cytotoxic chemotherapy (SSCC) as measured by the median time of\n      progression-free survival (PFS) in patients with chemotherapy refractory triple negative\n      (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer."
        }, 
        "brief_title": "Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women \u2265 18 years of age\n\n          2. Histologically documented breast cancer (either primary or metastatic site) that is\n             (i) ER-negative (0), (ii) PR-negative (0), and (iii) HER2-negative, defined by IHC\n             (immunohistochemistry; IHC 0/1, non-overexpressing) or FISH (fluorescence in situ\n             hybridization; FISH negative) or CISH (chromogen in situ hybridization; CISH\n             negative).\n\n          3. Expression of LHRH receptor confirmed by IHC on archival (or current biopsy of breast\n             tumor or metastatic site) breast cancer tissue\n\n          4. Progressive disease after failure of 1 to 3 prior chemotherapy regimens for recurrent\n             or metastatic (Stage IV) disease (prior adjuvant/neoadjuvant therapy is allowed)\n\n          5. Measurable disease by RECIST 1.1 criteria; at least one target lesion that has not\n             been previously irradiated.\n\n        Exclusion Criteria:\n\n          1. Eastern Cooperative Oncology Group (ECOG) performance status > 2\n\n          2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia or recent myocardial infarction (within 6 months of enrollment)\n\n          3. Leptomeningeal disease or brain metastases requiring steroids or other therapeutic\n             intervention\n\n          4. Left ventricular ejection fraction (LVEF) < 50 %, determined by echocardiogram or\n             MUGA scan\n\n          5. Compromised organ or marrow function as evidenced by any of the following:\n\n               -  thrombocyte count: < 100x109/L\n\n               -  absolute neutrophil count (ANC): < 1.5x109/L\n\n               -  hemoglobin: < 6.0 mmol/L (< 9 g/100 mL)\n\n               -  AS(A)T, AL(A)T: > 2.5 times upper limit of normal range (ULN) (> 5x ULN if\n                  clearly related to liver metastases)\n\n               -  bilirubin: > 1.5 mg/dL\n\n               -  creatinine: > 1.5 mg/dL or creatinine clearance < 40 mL/min.\n\n          6. Systemic anticancer therapy or radiotherapy within 21 calendar days of the first dose\n             of study drug*)\n\n             * also excluded are patients with anticipated ongoing concomitant anticancer therapy\n             during the study\n\n          7. Prior exposure to anthracyclines or anthracenediones for the treatment of metastatic\n             breast cancer including liposomal doxorubicin (Doxil), doxorubicin, daunorubicin, or\n             mitoxantrone\n\n          8. Prior adjuvant anthracyclines with a cumulative anthracycline dose \u2265 300 mg/m2\n\n          9. Ongoing therapeutic anticoagulation\n\n         10. Patients who are not surgically sterile or post-menopausal must agree to use for the\n             duration of the study reliable methods of birth control defined as:\n\n               -  complete abstinence\n\n               -  any intrauterine device (IUD) with published data showing that the lowest\n                  expected failure rate is < 1 % per year, or\n\n               -  any other methods with published data showing that the lowest expected failure\n                  rate is less than 1 % per year\n\n         11. Investigational therapy within 30 calendar days of the first scheduled day of\n             protocol treatment (investigational therapy is defined as treatment for which there\n             is currently no regulatory authority approved indication)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698281", 
            "org_study_id": "AEZS-108-049"
        }, 
        "intervention": [
            {
                "arm_group_label": "AEZS-108", 
                "intervention_name": "Zoptarelin doxorubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "nab-paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "eribulin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "pegylated liposomal doxorubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "vinorelbine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard single agent cytotoxic chemotherapy", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Gemcitabine", 
                "Vinorelbine", 
                "Capecitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6ttingen", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4ts-Frauenklinik"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany"
                    }, 
                    "name": "Klinik f\u00fcr Frauenheilkunde und Geburtshilfe"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.", 
        "overall_official": {
            "affiliation": "University of Miami", 
            "last_name": "Alberto J. Montero, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Efficacy of AEZS-108 compared to standard single agent cytotoxic chemotherapy (SSCC) as measured by the median time of progression-free survival.", 
            "safety_issue": "No", 
            "time_frame": "Up to two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "Up to two years"
            }, 
            {
                "measure": "Overall response of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "Up to two years"
            }, 
            {
                "measure": "Clinical benefit of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Duration of response of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Overall survival of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Toxicity of AEZS-108", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "AEterna Zentaris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AEterna Zentaris", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013", 
        "why_stopped": "Poor recruitment"
    }
}